Evidence map›Paper›PMID 36105886›Full record

ArticleTherapeutic advances in medical oncology2022

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.

Foteinos-Ioannis Dimitrakopoulos, Giannis Mountzios, Petros Christopoulos, Thomas Papastergiou, Mariam Elshiaty, Lea Daniello, Elefterios Zervas, Sofia Agelaki, Epaminondas Samantas, Adamantia Nikolaidi and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 15 institutions in 3 countries.

Foteinos-Ioannis DimitrakopoulosDivision of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece.ORCID https://orcid.org/0000-0003-2402-2549
Giannis MountziosSecond Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
Petros ChristopoulosDepartment of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, GermanyTranslational Lung Research Center Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-7966-8980
Thomas PapastergiouComputer Engineering and Informatics Department, University of Patras, Patras, Greece.
Mariam ElshiatyDepartment of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, GermanyTranslational Lung Research Center Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-5978-9251
Lea DanielloDepartment of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, GermanyTranslational Lung Research Center Heidelberg, Heidelberg, Germany.
Elefterios ZervasSeventh Respiratory Medicine Department and Asthma Center, Athens Chest Hospital Sotiria, Athens, Greece.
Sofia AgelakiDepartment of Medical Oncology, University General Hospital, Heraklion, Greece.
Epaminondas SamantasThird Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
Adamantia NikolaidiDepartment of Medical Oncology, Mitera Hospital, Athens, Greece.
Ilias AthanasiadisDepartment of Medical Oncology, Mitera Hospital, Athens, Greece.
Sofia BakaOncology Department, Interbalkan European Medical Center, Thessaloniki, Greece.
Konstantinos SyrigosOncology Unit, The Third Department of Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Athina ChristopoulouMedical Oncology Unit, S. Andrew Hospital, Patras, Greece.
Evangelos LianosDivision of Medical Oncology and Hematopoietic Cell Transplant Unit, Department of Medicine, "Metaxa" Cancer Hospital, Piraeus, Greece.
Konstantinos SamitasSeventh Respiratory Medicine Department and Asthma Center, Athens Chest Hospital Sotiria, Athens, Greece.
Nikolaos TsoukalasMedical Oncology Unit, Veterans (NIMTS) Hospital, Athens, Greece.
Eleni-Isidora PerdikouriOncology Department, General Hospital of Volos, Volos, Greece.
George OikonomopoulosSecond Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
Anastasia KottorouDivision of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece.
Foteini KalofonouDepartment of Oncology, Imperial College NHS Healthcare Trust, Charing Cross Hospital, London, UK.
Thomas MakatsorisDivision of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece.
Angelos KoutrasDivision of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece.
Vasileios MegalooikonomouComputer Engineering and Informatics Department, University of Patras, Patras, Greece.
Haralabos KalofonosDivision of Oncology, Department of Medicine, University Hospital of Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Rion-Patras, Patras, Achaia 26504, Greece.
University of Patras · GRHeidelberg University · DEMitera Hospital · GRSotiria General Hospital · GRAgios Pavlos General Hospital · GRCharing Cross Hospital · GBGeneral University Hospital of Patras · GRHenry Dunant Hospital · GRHospital Agioi Anargyroi · GRInterbalkan Medical Center · GRMetaxa Hospital · GRMetropolitan Hospital · GRNational and Kapodistrian University of Athens · GRNIMTS Hospital · GRUniversity Hospital of Heraklion · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recently, the Patras Immunotherapy Score (PIOS) has been developed to estimate the survival benefit of patients with advanced non-small-cell lung cancer (aNSCLC) treated with nivolumab or pembrolizumab. The aim of this study was to validate the clinical value of PIOS in an external cohort of aNSCLC patients. Methods: PIOS is a baseline formula produced by the combination of performance status, body mass index, age and line of treatment. In this multicentre study, 626 patients with confirmed NSCLC pathology, who had been treated with nivolumab or pembrolizumab, as well as 444 patients with aNSCLC, who had been managed with chemotherapy alone, were retrospectively enrolled. Predictive and prognostic values of PIOS were finally evaluated. Results: Patients treated with immunotherapy and higher PIOS score had an improved progression-free survival not only in univariate [hazard ratio (HR) = 0.621, Conclusions: This study provides further validation of PIOS in aNSCLC patients treated with anti-PD-1 monotherapy.

Indexed as

biomarkernivolumabNSCLCPatras Immunotherapy ScorepembrolizumabPIOS

Identifiers

PMID36105886
PMCPMC9465562
OpenAlexW4295899323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.